Surgical Repair vs. Non-Surgical Treatment for Rotator Cuff Tears: Is Surgery Worth the Cost?

By HEOR Staff Writer

January 28, 2023

Rotator cuff repair analysis

The rotator cuff, a critical component of the shoulder, plays a crucial role in stabilising the joint and facilitating arm movement. When it tears, patients face a decision: to opt for surgical repair or non-surgical treatment. This rotator cuff repair analysis presents a detailed review of both methods, shedding light on their effectiveness, safety, and cost-effectiveness.

Understanding Rotator Cuff Tears

Low-to-moderate-certainty evidence suggests that surgical repair does not result in clinically relevant differences in effect compared to non-surgical treatment for degenerative rotator cuff tears. An HTA from the Norwegian institute of public health showed that choosing exclusively non-surgical treatment over surgery can provide up to NOK 81 million in annual cost savings.

Research suggests that there are no clinically relevant differences in effect between surgical and non-surgical treatment. Few serious adverse events were reported, but we are uncertain about the absolute risks. Surgery is the most expensive alternative, and choosing non-surgical treatment over surgery can provide significant cost savings.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This